Regenerative Medicine Market by Product Type (Cell Therapy, Gene Therapy, Tissue Engineering, and Small Molecule & Biologic), Material (Synthetic Material, Biologically Derived Material, Genetically Engineered Material, and Pharmaceuticals), Application (

Regenerative Medicine Market by Product Type (Cell Therapy, Gene Therapy, Tissue Engineering, and Small Molecule & Biologic), Material (Synthetic Material, Biologically Derived Material, Genetically Engineered Material, and Pharmaceuticals), Application (Cardiovascular, Oncology, Dermatology, Musculoskeletal, Wound Healing, Ophthalmology, Neurology, and Others) and End user (Hospitals, Ambulatory Surgical Centers, and Others: Global Opportunity Analysis and Industry Forecast, 2021–2030

The regenerative medicine market was valued at $10,107.32 million in 2020, and is estimated to reach $83,196.72 million by 2030, growing at a CAGR of 23.4% from 2021 to 2030. Regenerative medicines are used to repair, replace, and regenerate tissues and organs affected by injury, disease, or natural aging process. These medicines restore the functionality of cells & tissues and are used in several degenerative disorders, such as dermatology, neurodegenerative diseases, cardiovascular, and orthopedic applications. Stem cells are capable of proliferation and differentiation, which increase their importance in this field.

Increase in prevalence of musculoskeltal diseases, oncological disorders, and dental disorders is the major factor that contributes in the growth of the regenerative medicine market. Moreover, other factors that fuel the market growth include, increase in adoption of regenerative medicine products and technological advancement in stem cell-based therapies that have revolutionized the perspective research towards regenerative medicine. In addition, many companies are increasing their market presence, thereby expanding their business across new markets. For instance, in July 2021, Pharming Group N.V and Orchard collaborated for the development of commercialized OTL 105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Such factors have led to the growth of the regenerative medicine market.

Emergence of stem cell technology, untapped potential of nanotechnology, increase in prevalence of chronic diseases & trauma emergencies, advancement in monitoring devices and surgical technologies, rise in incidence of degenerative diseases, and shortage of organs for transplantation are major factors that drive the growth of the regenerative medicine market. Increase in focus on stem cells and growth in R&D activities in emerging economies are expected to supplement the market growth in the coming years. Developing nations are focused on technological advancements, which is expected to boost the market growth, globally. However, stringent government regulations, operational inefficiency, and high cost of treatment of regenerative medicines are estimated to hamper the growth of the regenerative medicine market.

Conversely, development of cost-effective therapeutics through large-scale production and high market potential in untapped emerging economies are expected to provide lucrative growth opportunities for the market. People, nowadays are becoming more health conscious, which compels them to maintain their health condition. Thus increasing the demand for regenerative medicine. This has further encouraged many key players to enter emerging markets, thus offering a lucrative growth opportunity in the regenerative medicine market.

The regenerative medicine market is segmented on the basis of product type, material, application, and geography. On the basis of product type, the market is classified into cell therapy, gene therapy, tissue engineering, and small molecule & biologic.

On the basis of material, the market is categorized into synthetic material, biologically derived material, genetically engineered material, and pharmaceutical. Synthetic material is further divided into biodegradable synthetic polymer, scaffold, artificial vascular graft material, and hydrogel material. Biologically derived material is further bifurcated into collagen and xenogenic material. Genetically engineered material is further segmented into deoxyribonucleic acid, transfection vector, genetically manipulated cell, three-dimensional polymer technology, transgenic, fibroblast, neural stem cell, and gene-activated matrices. Pharmaceutical is further divided into small molecule and biologic.

On the basis of application, the market is categorized into cardiovascular, oncology, dermatology, musculoskeletal, wound healing, ophthalmology, neurology, and others. On the basis of region, the market is analyzed across four regions, such as North America, Europe, Asia-Pacific, and LAMEA.

By material, the biologically derived material was the dominant segment in 2020, and is estimated to maintain this trend during the forecast period. The demand for genetically engineered material has increased due to their unique, such as promotion of cellular interactions, rise in proliferation, and differentiation of cells that facilitate self-assembly into directionally organized structures, and control the manipulation of cellular behavior.

By application the musculoskeletal application segment accounted for the largest share in 2020, whereas cardiovascular is expected to be the fastest-growing segment, registering a CAGR of 23.8% during the forecast period.

The use of regenerative medicine is highest in North America, particularly in the U.S., owing to increase in prevalence of chronic disorders, rise in demand for artificial organs due to organ failure, and presence of highly sophisticated healthcare infrastructure. Although the use of regenerative medicine in Asia-Pacific and LAMEA is low, the adoption rate is expected to increase due to the presence of high unmet medical needs and constant improvement in the healthcare infrastructure to treat chronic disorders. In addition, countries such as China, India, Australia, and Japan contribute to the market growth owing to their large population and rise in demand for tissue-engineered and regenerative medicine products. These countries have varying demographics and cultural conditions, which highly influence their respective markets.

The key players operating in the global regenerative medicine market include Stryker Corporation, Zimmer Biomet Holdings, Inc., Medtronic Plc., Athersys, Inc., U.S. Stem Cell, Inc. (Bioheart, Inc.), Organogenesis, Inc. (Advanced Biohealing), Integra Lifesciences Holdings Corporation, Acelity Holdings, Inc., Isto Biologics (Isto Biologics Medical Systems, Inc.), and CryoLife, Inc.

Other prominent players in the value chain include Shimadzu Recursion Pharmaceuticals, Inc., Baxter International, Inc., DePuy Synthes Siemens Healthineers, General Electric (GE) Company, Koninklijke Philips N.V., Cloudmedx, Inc., and Bay Labs, Inc.

KEY BENEFITS FOR STAKEHOLDERS

This report provides an extensive analysis of the current and emerging market trends and dynamics in the global albumin market to identify the prevailing opportunities.
This study presents the competitive landscape of the global market to predict the competitive environment across geographies.
Comprehensive analysis of factors that drive and restrict the market growth is provided.
Region- & country-wise analysis is provided to understand the market trends and dynamics.

KEY MARKET SEGMENTS


By Product Type

Cell Therapy
Gene Therapy
Tissue Engineering
Small Molecule & Biologic

By Material

Synthetic Material
Biodegradable Synthetic Polymer
Scaffold
Artificial Vascular Graft Material
Hydrogel Material
Biologically Derived Material
Collagen
Xenogeneic Material
Genetically Engineered Material
Deoxyribonucleic Acid Transfection Vector
Genetically Manipulated Cell
Three-Dimensional Polymer Technology
Pharmaceutical
Small Molecule
Biologic

BY Application

Cardiovascular
Oncology
Dermatology
Musculoskeletal
Wound Healing
Ophthalmology
Neurology
Others

By End user

Hospitals
Ambulatory Surgical Center
Others

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

KEY MARKET PLAYERS

3 M
Athersys Inc
Cryo Life Inc
Integra Life Sciences
Isto Biologics
Medtronic Plc
Organogenesis
Stryker Corporation
US Stem Cell Inc
Zimmer Biomet Holdings Inc.